If you or someone you know has vitiligo, a new treatment could finally make a visible difference. China Medical System Holdings Limited’s subsidiary, Dermavon, just won approval from China’s National Medical Products Administration for ruxolitinib phosphate cream, the first and only targeted drug for non-segmental vitiligo in China.
That’s a potential game-changer for more than 10 million vitiligo patients in the country, 8.2 million of whom have the non-segmental form. The cream works as a selective JAK1/JAK2 inhibitor and is already recognized by the U.S. FDA and European Medicines Agency for repigmentation.
Clinical data shows real results. Two overseas Phase III trials reported 29.9 percent of patients achieving significant skin repigmentation after 24 weeks, far above placebo groups at 7.5 and 12.9 percent. Longer-term use up to 52 weeks showed continued improvement, and domestic studies in China confirmed similar outcomes.
Dermavon isn’t stopping there. Its Phase III trial for mild to moderate atopic dermatitis has also shown positive results, and the company is pursuing approval for that treatment too. The firm holds an exclusive license with Incyte to develop and commercialize ruxolitinib phosphate cream across Mainland China, Hong Kong, Macau, Taiwan, and 11 Southeast Asian countries.
Since 2021, Dermavon has grown fast, positioning itself as a leader in China’s skin health market. CMS plans a spin-off and separate listing on the Hong Kong Stock Exchange to unlock its value. With roughly 40 innovative products in its pipeline, CMS is pushing to expand beyond China, targeting Southeast Asia and the Middle East next.
For patients and families dealing with vitiligo, the approval isn’t just a regulatory milestone. It’s a rare, science-backed option that could finally change what daily life looks like for millions.
Discover more from TBC News
Subscribe to get the latest posts sent to your email.
